Stock Detail
DISCOVERY LABORATORIES INC
Drugs
DSCO @ Yahoo Finance | DSCO Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.69 | $1.77 | $-0.03 | -1.75% | 0.00 | $1.72 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.73 | $1.69 | 132,269 | 40.96M | 153,071.5 | -1.44 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 1.80 | 1.75 | 1.72 | 1.67 | 1.64 |
Stock Profile
Discovery Laboratories, Inc., a biopharmaceutical company, develops Surfactant Replacement Therapies for respiratory diseases. The company offers Surfaxin, a protein B-based agent, for the prevention of respiratory distress syndrome in premature infants. Discovery Laboratories provides Surfaxin, which is in Phase 2 clinical trials, for bronchopulmonary dysplasia in premature infants, neonatal respiratory disorders in premature infants, and prophylactic/early treatment of meconium aspiration syndrome in full-term infants. It also offers its products for the treatment of acute respiratory distress syndrome in adults in the intensive care unit, as well as a Phase 1b trial of its lung surfactant delivered as an inhaled aerosol for patients who suffer from asthma. In addition, the company evaluating the development of aerosolized formulations of its SRT to prevent or treat acute lung injury, COPD, rhinitis, sinusitis, sleep apnea, and otitis media. It has a strategic alliance with Quintiles Transnational Corp.; PharmaBio Development, Inc.; Chrysalis Technologies; and Laboratorios del Dr. Esteve S.A. The company is headquartered in Warrington, Pennsylvania.